国泰海通证券发布研报称，自精锋多孔腔镜手术机器人于2022年12月商业化以来，于2024年在中国售出 了20台精锋多孔腔镜手术机器人，在国内手术机器人制造商中排名第一。此外，2025年以来，精锋医疗 国际化引擎全速启动，海外订单量迎来爆发式增长，截至2025年底，公司已签订的118台核心产品的全 球销售协议中，海外国家占72台。 精锋医疗-B(02675)午后涨超12%，截至发稿，涨11.33%，报64.85港元，成交额3517.46万港元。 消息面上，国家医保局近日出台手术机器人收费指南。国信证券表示，受益于手术机器人行业技术革 新、临床需求及政策红利，全球及中国市场规模持续高速增长，其中中国单孔及自然腔道机器人细分赛 道增速尤为突出。建议积极关注国产手术机器人厂家的进口替代及出海进程。 ...

国泰海通证券发布研报称，自精锋多孔腔镜手术机器人于2022年12月商业化以来，于2024年在中国售出 了20台精锋多孔腔镜手术机器人，在国内手术机器人制造商中排名第一。此外，2025年以来，精锋医疗 国际化引擎全速启动，海外订单量迎来爆发式增长，截至2025年底，公司已签订的118台核心产品的全 球销售协议中，海外国家占72台。 智通财经APP获悉，精锋医疗-B(02675)午后涨超12%，截至发稿，涨11.33%，报64.85港元，成交额 3517.46万港元。 消息面上，国家医保局近日出台手术机器人收费指南。国信证券表示，受益于手术机器人行业技术革 新、临床需求及政策红利，全球及中国市场规模持续高速增长，其中中国单孔及自然腔道机器人细分赛 道增速尤为突出。建议积极关注国产手术机器人厂家的进口替代及出海进程。 ...

国产手术机器人引领者，规模化出海启程 精锋医疗-B(2675) 精锋医疗首次覆盖报告 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | [Table_Invest] 评级： | 增持 | | --- | --- | --- | --- | --- | --- | | 江珅(分析师) | 021-23185638 | jiangshen@gtht.com | S0880525090001 | | | | 赵峻峰(分析师) | 0755-23976629 | zhaojunfeng@gtht.com | S0880519080017 | [当前价格 Table_CurPrice] (港元)： | 58.80 | | 余文心(分析师) | 021-38676666 | yuwenxin@gtht.com | S0880525040111 | | | 本报告导读： 公司是国内手术机器人引领者，通过持续技术革新推动外科手术进步，全球临床手 术量快速爬升，伴随国内销量增长以及海外市场的商业化，公司收入获得快速增长。 [Table_PicQuote] 52周股价走势图 投资要点： 风险提示。临床 ...

成熟商业化团队及分销网络构建，海外订单爆发式增长 精锋医疗于2017年5月在深圳创立，是中国自主研发手术机器人领域的深耕者，为中国首家、全球第二 家同时取得多孔腔镜手术机器人、单孔腔镜手术机器人及自然腔道手术机器人注册审批的公司，已构建 多孔+单孔+远程系统的"三合一"外科手术解决方案。公司全球首创的单多孔手术机器人超级系统 MSP2000已于2025年10月获得CE证，为全球手术机器人的技术演进与临床应用提供创新范本。 24年国内厂商销量第一，持续落地中国顶级医院圈层 自精锋多孔腔镜手术机器人于2022年12月商业化以来，于2024年在中国售出了20台精锋多孔腔镜手术机 器人，在国内手术机器人制造商中排名第一，临床应用范围已覆盖全国30个省份，超过220家医院，包 括国内顶尖三甲医院乃至多个省份的县域基层医院，实现了"省-市-县"三级医院网络的全覆盖。伴随国 内销量大幅增长以及海外的商业化，公司总收入由2023年的0.48亿元增加至2024年的1.6亿元，并由 2024H1的0.30亿元增加至2025H1的1.49亿元。 国泰海通证券发布研报称，首次覆盖精锋医疗-B(02675)给予评级为"增持"。预测公司 ...

自精锋多孔腔镜手术机器人于2022年12月商业化以来，于2024年在中国售出了20台精锋多孔腔镜手术机 器人，在国内手术机器人制造商中排名第一，临床应用范围已覆盖全国30个省份，超过220家医院，包 括国内顶尖三甲医院乃至多个省份的县域基层医院，实现了"省-市-县"三级医院网络的全覆盖。伴随国 内销量大幅增长以及海外的商业化，公司总收入由2023年的0.48亿元增加至2024年的1.6亿元，并由 2024H1的0.30亿元增加至2025H1的1.49亿元。 智通财经APP获悉，国泰海通证券发布研报称，首次覆盖精锋医疗-B(02675)给予评级为"增持"。预测公 司2025-2027年的收入分别为4.32、8.11、12.36亿元，参考可比公司，考虑公司产品布局领先，海外进 展迅速，给予公司2026年35XPS，对应目标价73.20元/79.57港元（汇率为1港元=0.92人民币）。 国泰海通证券主要观点如下： 国产手术机器人引领者，持续革新推动技术进步 精锋医疗于2017年5月在深圳创立，是中国自主研发手术机器人领域的深耕者，为中国首家、全球第二 家同时取得多孔腔镜手术机器人、单孔腔镜手术机器人及自然腔道手术 ...

Investment Rating - The report assigns an "Accumulate" rating to the company [1][11][6]. Core Insights - The company is a leader in domestic surgical robotics, driving advancements in surgical procedures through continuous technological innovation. With rapid growth in global clinical surgical volumes, the company is experiencing significant revenue growth alongside increasing domestic sales and commercialization in overseas markets [2][11]. Summary by Sections 1. Domestic Surgical Robotics Leader - The company was founded in May 2017 in Shenzhen and is the first in China and the second globally to obtain regulatory approval for multi-port, single-port, and natural orifice surgical robots. It has developed a "three-in-one" surgical solution combining multi-port, single-port, and remote systems [15][11]. - The company has achieved the highest sales volume among domestic manufacturers in 2024, with 20 units of its multi-port surgical robot sold in China, covering over 220 hospitals across 30 provinces [11][29]. - Revenue is projected to grow from RMB 0.48 billion in 2023 to RMB 1.6 billion in 2024, driven by increased sales and market acceptance of its products [29][30]. 2. Clinical Advantages of Surgical Robots - Surgical robots provide significant clinical benefits, including high precision, stability, and repeatability, which traditional laparoscopic surgeries struggle to achieve. This technology is transforming the landscape of minimally invasive surgeries [38][39]. 3. International Expansion and Sales Growth - The company has successfully entered overseas markets, securing five orders in 2024 and establishing a distribution network across five continents. By the end of 2025, it had signed global sales agreements for 118 units, with 72 units designated for international markets [11][29]. - The company’s internationalization efforts have marked a transition from initial market testing to large-scale expansion [11][29]. 4. Financial Projections - Revenue forecasts for 2025, 2026, and 2027 are RMB 4.32 billion, RMB 8.11 billion, and RMB 12.36 billion, respectively, reflecting substantial growth rates of 170% and 88% in the following years [4][11]. - The company is expected to turn profitable by 2026, with net profit projected to reach RMB 167 million by 2027, following a loss of RMB 219 million in 2024 [4][11]. 5. Management Team and R&D Strength - The management team, led by experienced founders, has built a proprietary technology platform supported by a multidisciplinary R&D team of 265 members. The company holds the highest number of patents in the Chinese surgical robotics sector [20][25]. - The company has established a comprehensive technology platform based on seven proprietary core technology modules, enhancing its competitive edge in the market [26][27].

Group 1: IPO Highlights - Beijing Zhiyu Huazhang Technology Co., Ltd. (Zhiyu) officially listed on the Hong Kong Stock Exchange on January 8, 2026, under the stock code "2513," becoming the "first global large model stock" [2] - Zhiyu plans to issue 37,419,500 H-shares, with a public offering in Hong Kong receiving 1,159.46 times subscription and international offering receiving 15.28 times subscription, raising over 4.3 billion HKD at an issue price of 116.2 HKD per share [2] - Shanghai Tianshu Zhixin Semiconductor Co., Ltd. (Tianshu) also listed on January 8, 2026, under the stock code "9903," issuing 25,431,800 shares with a public offering subscription of 414.24 times and international offering of 10.68 times [5] - MiniMax Group Inc. (MiniMax) listed on January 9, 2026, under the stock code "0100," becoming the largest AI large model company by IPO scale in history [7] - Shenzhen Jingfeng Medical Technology Co., Ltd. (Jingfeng) listed on January 8, 2026, under the stock code "2675," issuing 27,722,200 H-shares with a public offering subscription of 1,091.94 times and international offering of 25.18 times [9] Group 2: Company Performance and Growth - Zhiyu has achieved a revenue growth from 0.57 million CNY in 2022 to 3.12 million CNY in 2024, with a compound annual growth rate (CAGR) of 130% [3] - Tianshu's revenue increased from 1.89 billion CNY in 2022 to 5.40 billion CNY in 2024, with a CAGR of 68.8% [6] - MiniMax's revenue grew from 3.5 million USD in 2023 to 30.5 million USD in 2024, representing a year-on-year increase of 782.2% [7] - Jingfeng's revenue for the first half of 2025 reached approximately 149 million CNY, a nearly 400% year-on-year increase [10] Group 3: Market Position and Future Outlook - Zhiyu is recognized as the largest independent large model vendor in China, with significant market advantages in the enterprise sector [4] - Tianshu's products have been deployed in over 900 instances across key sectors, indicating a strong market presence [6] - MiniMax has established a user base of over 2.12 million individuals and 130,000 enterprise clients across more than 200 countries [7] - Jingfeng's robotic surgical systems have been used in over 12,000 surgeries, indicating a growing integration into standard surgical practices [9]

Group 1: IPO Dynamics - Beijing Zhipu Huazhang Technology Co., Ltd. (Zhipu) officially listed on the Hong Kong Stock Exchange on January 8, 2026, with the stock code "2513," becoming the "first global large model stock" [3] - Zhipu plans to issue 37,419,500 H-shares, with a subscription rate of 1,159.46 times for public offerings in Hong Kong and 15.28 times for international offerings, raising over HKD 4.3 billion at an issue price of HKD 116.2 per share [3] - Zhipu's revenue from 2022 to 2024 is projected to grow from CNY 0.57 billion to CNY 3.12 billion, with a compound annual growth rate (CAGR) of 130% [4] Group 2: Market Position and Growth - The domestic large language model market is expected to grow 20 times in the next six years, with enterprise demand leading the way, providing Zhipu with a competitive advantage [5] - Zhipu's revenue is expected to exceed USD 100 million in 2025, with projections of approximately CNY 1.6 billion and CNY 2.7 billion for 2026 and 2027, respectively [5] Group 3: Other Companies' IPOs - Shanghai Tianshu Zhixin Semiconductor Co., Ltd. (Tianshu) also listed on January 8, 2026, with a total issuance of 25,431,800 shares and a subscription rate of 414.24 times for public offerings in Hong Kong [7] - Tianshu's revenue grew from CNY 1.89 billion in 2022 to CNY 5.40 billion in 2024, with a CAGR of 68.8% [9] - MiniMax Group Inc. (MiniMax) listed on January 9, 2026, with a total issuance of 29,197,600 shares, achieving a subscription rate of 1,837.17 times for public offerings in Hong Kong [10] - MiniMax's revenue is projected to grow from USD 3.5 million in 2023 to USD 30.5 million in 2024, with a year-on-year increase of 782.2% [11] Group 4: Financial Performance - Shenzhen Jingfeng Medical Technology Co., Ltd. (Jingfeng) listed on January 8, 2026, with a revenue of approximately CNY 1.49 billion in the first half of 2025, representing a nearly 400% year-on-year growth [14] - Hunan Mingming Hen Mang Commercial Chain Co., Ltd. (Mingming) achieved a retail sales volume of CNY 661 billion in the first three quarters of 2025, a year-on-year increase of 74.5% [17] - Hunan Sangnisendi Group Co., Ltd. (Sangnisendi) reported revenues of CNY 1.07 billion and CNY 2.45 billion for 2023 and 2024, respectively, with a year-on-year growth of 129.5% [24] Group 5: Industry Insights - The AI and semiconductor sectors are experiencing rapid growth, with companies like Zhipu and Tianshu leading innovations in large models and computing power [4][9] - The food and beverage retail sector is also expanding, with companies like Mingming and COMMUNE establishing significant market positions [17][21] - The medical technology field is advancing with companies like Jingfeng and DeShi Biotech focusing on robotic surgery and AI in medical imaging [14][35]

Core Insights - Three companies, Zhiyu, Tianshu Zhixin, and Jingfeng Medical-B, successfully listed on the Hong Kong Stock Exchange on January 8, 2026, with first-day gains of 13.17%, 8.44%, and 30.90% respectively [1][4]. Company Summaries - **Zhiyu**: As the world's first publicly listed company focused on a general artificial intelligence (AGI) foundational model, Zhiyu has gained significant attention from investors. The company, founded in 2019, has developed a 100 billion parameter model (GLM-130B) and supports over 8,000 institutional clients and approximately 80 million devices. It holds a 6.6% market share among independent general model developers in China, ranking first in the country and second globally based on projected 2024 revenue [5][6]. - **Tianshu Zhixin**: This company specializes in providing general GPU products and AI computing solutions across various industries. Its product lineup includes general GPU chips and customized AI computing solutions, with over 52,000 GPU products delivered to more than 290 clients across sectors such as finance, healthcare, and transportation. Tianshu Zhixin has achieved over 900 deployments and applications in critical fields, supporting industrial digital transformation [6][7]. - **Jingfeng Medical-B**: Established in 2017, Jingfeng Medical-B is a leading company in the surgical robotics sector. It is the first in China and the second globally to receive regulatory approval for multiple types of surgical robots. The company's core product, the Jingfeng multi-port laparoscopic surgical robot, received approval in December 2022 and has expanded its clinical applications. In 2024, it sold 20 units, ranking first among domestic surgical robot manufacturers [7][8]. Market Reception - All three companies experienced strong demand during their public offerings, with Zhiyu and Jingfeng Medical-B achieving over 1,000 times oversubscription in the public offering phase, while Tianshu Zhixin had an oversubscription of 414.24 times [8][9]. - The strong performance of these IPOs has contributed to a positive sentiment in the Hong Kong IPO market, with expectations that upcoming listings may also perform well [4][11]. Institutional Interest - The three companies attracted significant interest from institutional investors, with Zhiyu securing a diverse base of cornerstone investors, including major public funds and private equity firms, totaling HKD 2.98 billion in subscriptions [9][10]. - Tianshu Zhixin and Jingfeng Medical-B also have backing from prominent institutions such as UBS and the Abu Dhabi Investment Authority, indicating strong confidence in their business models and growth potential [10]. Upcoming Listings - The Hong Kong market is witnessing a surge in new listings, with additional companies set to debut shortly after the successful IPOs of Zhiyu, Tianshu Zhixin, and Jingfeng Medical-B [11][12].

Core Insights - The article highlights the emergence of Shenzhen-based Jingfeng Medical as a key player in the global surgical robot market, leveraging over 600 patents to reshape the competitive landscape dominated by foreign brands [1][2]. Company Overview - Jingfeng Medical, established in 2017, focuses on the design, research, and manufacturing of surgical robots, with a product matrix that includes multi-port and single-port laparoscopic surgical robots, as well as natural orifice surgical robots [2]. - The company is the first in China and the second globally to obtain regulatory approval for all three types of surgical robots, positioning its technology among the world's top tier [2]. Market Trends - The penetration rate of robotic-assisted laparoscopic surgery in China is currently low at 0.7% in 2024, with expectations to rise to 3.0% by 2033, compared to 21.9% in the U.S. in 2024, indicating significant growth potential for domestic companies like Jingfeng Medical [3]. Commercialization and Financial Performance - Jingfeng Medical began commercializing its multi-port laparoscopic surgical robot in December 2022, achieving a leading position in the domestic market with 20 units sold in 2024 [4]. - The company reported revenues of 48.04 million yuan in 2023, projected to increase to 160 million yuan in 2024, with a 400% year-on-year growth in the first half of 2025 [4][5]. - The revenue structure shows that 92.9% comes from surgical robot sales, with significant contributions from overseas markets, indicating successful global expansion [5]. Investment and Funding - Jingfeng Medical has raised over 2 billion yuan through six rounds of financing, attracting investments from notable institutions such as Sequoia China and Temasek [6]. - The recent IPO attracted a strong base of cornerstone investors, reflecting high market confidence in the company's technological capabilities and growth potential [6]. Competitive Landscape - The company has established a formidable competitive barrier with its complete product matrix of multi-port, single-port, and natural orifice surgical robots, being the only company in China and one of two globally to have all these products approved [8]. - The potential for high returns is emphasized, with expectations of continued growth driven by increased penetration of robotic-assisted surgeries and expansion into international markets [8].